Clinical Trials
6 trialsNCT03066206 2026-02-20
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03318939 2024-04-03
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT03744715 2024-03-05
A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT03429101 2021-01-15
A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
Spectrum Pharmaceuticals, Inc
Phase 1 Terminated
NCT04044170 2020-11-17
Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Hanmi Pharmaceutical Company Limited
Phase 2 Terminated
NCT01819428 2016-03-01
NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
National OncoVenture
Phase 2 Terminated